Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 dose-ranging crossover study of CINRYZE for prevention of hereditary angioedema attacks in children
2013-002453-29Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoint: Number of angioedema attacks normalized to a 12-week treatment period. Started Dec 2013; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2013-002453-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002453-29.